Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 7 for:    ADS-5102 Amantadine

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03436199
Recruitment Status : Completed
First Posted : February 19, 2018
Last Update Posted : April 20, 2020
Sponsor:
Information provided by (Responsible Party):
Adamas Pharmaceuticals, Inc.

Brief Summary:
This is a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group study of ADS-5102 (amantadine extended release [ER] capsules) in MS patients with walking impairment. ADS-5102 will be administered once daily at bed time.

Condition or disease Intervention/treatment Phase
Walking Impairment Multiple Sclerosis Drug: ADS-5102, 137 mg Drug: ADS-5102, 274 mg Other: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 594 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment
Actual Study Start Date : March 29, 2018
Actual Primary Completion Date : December 10, 2019
Actual Study Completion Date : December 10, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ADS-5102 137 mg Drug: ADS-5102, 137 mg
Oral capsules to be administered once daily at bedtime
Other Names:
  • ADS-5102
  • amantadine HCl extended release

Experimental: ADS-5102 274 mg Drug: ADS-5102, 274 mg
Oral capsules to be administered once daily at bedtime
Other Names:
  • ADS-5102
  • amantadine HCl extended release

Placebo
placebo capsules
Other: Placebo
Oral capsules to be administered once daily at bedtime




Primary Outcome Measures :
  1. Timed 25 foot walk (T25FW, feet/second) [ Time Frame: 12 weeks ]
    The T25FW is a measure of lower extremity function. The subject is directed to a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The task is immediately administered again by having the subject walk back the same distance. The result is reported as time to complete (seconds) or speed (feet per second). Improvement is indicated by a decrease in time or an increase in speed.


Secondary Outcome Measures :
  1. Timed Up and Go (TUG) [ Time Frame: 12 weeks ]
    The TUG is a measure of lower extremity strength, balance, and coordination. The subject stands up from a chair, walks 3 meters then turns around and walks back to the chair to sit down. The result is reported in seconds. Improvement is indicated by negative change scores.

  2. 2-Minute Walk Test (2MWT) [ Time Frame: 12 weeks ]
    The 2MWT is a measure of lower extremity function. The subject is instructed to walk as far as possible in 2 minutes, and the distance is measured in meters. Improvement is indicated by positive change scores.

  3. Multiple Sclerosis Walking Scale-12 (MSWS-12) [ Time Frame: 12 weeks ]
    The MSWS-12 is a 12-item walking scale that is a measure of subject-reported walking ability during the past 2 weeks. Each item is scored on a 1 to 5 scale. A total score can be generated and transformed to a 0 to 100 scale. Improvement is indicated by negative change scores.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed a current IRB-approved informed consent form
  • Male or female subjects between 18 and 70 years of age, inclusive, at the time of Screening
  • Confirmed diagnosis of MS according to the 2017 McDonald criteria
  • Current medication regimen must be stable for at least 30 days prior to screening, and subject must be willing to continue the same dosing regimen for the duration of study participation
  • Maximum Expanded Disability Status Scale (EDSS) score during screening of 6.5
  • Stable physical activity level (inclusive of prescribed physical therapy) for at least 30 days prior to screening and willing to continue without change for the duration of study participation
  • A score on each of two completed screening T25FW tests between 8 and 45 seconds, inclusive

Exclusion Criteria:

  • Documented inability to tolerate amantadine
  • Clinically significant MS relapse with onset less than 30 days prior to screening
  • Receipt of dalfampridine (or any 4-aminopyridine or 2,4-diaminopyridine preparation) or amantadine within 30 days prior to screening
  • History of seizures within 3 years prior to screening
  • History of hallucinations (visual, auditory, or any other type) within 3 years prior to screening
  • History of bipolar disorder, schizophrenia, or psychosis, regardless of treatment
  • For subjects with a history of major depressive disorder, the presence of active depressive symptoms that, in the opinion of the investigator, would affect the subject's ability to complete study assessments, or which would not be in the subject's best interest to participate in the study
  • Presence of orthostatic hypotension at screening: a decrease in systolic blood pressure (at least 20 mm Hg) or diastolic blood pressure (at least 10 mm Hg) within 3 minutes of the subject standing up, compared to pressures obtained while sitting
  • If female, is pregnant or lactating
  • If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from screening through at least 4 weeks after the completion of study treatment. If a sexually active male, does not agree to utilize condoms from screening through at least 4 weeks after the completion of study treatment.
  • Treatment with an investigational drug or device within 30 days prior to screening
  • Treatment with an investigational biologic within 6 months or 5 half-lives, whichever is longer, prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03436199


Locations
Hide Hide 84 study locations
Layout table for location information
United States, Alabama
Adamas Clinical Site
Cullman, Alabama, United States, 35058
United States, Arizona
Adamas Clinical Site
Phoenix, Arizona, United States, 85032
Adamas Clinical Site
Scottsdale, Arizona, United States, 85251
Adamas Clinical Site
Tucson, Arizona, United States, 85704
United States, California
Adamas Clinical Site
Carlsbad, California, United States, 92011
Adamas Clinical Site
Fresno, California, United States, 93710
Adamas Clinical Site
Fullerton, California, United States, 92835
Adamas Clinical Site
Long Beach, California, United States, 90806
Adamas Clinical Site
Newport Beach, California, United States, 92663
Adamas Clinical Site
Sacramento, California, United States, 95817
United States, Colorado
Adamas Clinical Site
Aurora, Colorado, United States, 80045
Adamas Clinical Site
Colorado Springs, Colorado, United States, 80907
Adamas Clinical Site
Denver, Colorado, United States, 80209
Adamas Clinical Site
Fort Collins, Colorado, United States, 80528
United States, Connecticut
Adamas Clinical Site
Fairfield, Connecticut, United States, 06824
Adamas Clinical Site
New London, Connecticut, United States, 06320
United States, District of Columbia
Adamas Clinical Site
Washington, District of Columbia, United States, 20007
United States, Florida
Adamas Clinical Site
Maitland, Florida, United States, 32751
Adamas Clinical Site
Miami, Florida, United States, 33136
Adamas Clinical Site
Naples, Florida, United States, 34105
Adamas Clinical Site
Orlando, Florida, United States, 32806
Adamas Clinical Site
Ormond Beach, Florida, United States, 32174
Adamas Clinical Site
Palm Coast, Florida, United States, 32164
Adamas Clinical Site
Port Charlotte, Florida, United States, 33952
Adamas Clinical Site
Sarasota, Florida, United States, 34233
Adamas Clinical Site
Tampa, Florida, United States, 33609
Adamas Clinical Site
Vero Beach, Florida, United States, 32960
United States, Georgia
Adamas Clinical Site
Atlanta, Georgia, United States, 30309
Adamas Clinical Site
Savannah, Georgia, United States, 31406
United States, Illinois
Adamas Clinical Site
Northbrook, Illinois, United States, 60062
United States, Indiana
Adamas Clinical Site
Indianapolis, Indiana, United States, 46256
United States, Kansas
Adamas Clinical Site
Kansas City, Kansas, United States, 66160
Adamas Clinical Site
Lenexa, Kansas, United States, 66214
Adamas Clinical Site
Overland Park, Kansas, United States, 66212
United States, Massachusetts
Adamas Clinical Site
Foxboro, Massachusetts, United States, 02035
Adamas Clinical Site
Lexington, Massachusetts, United States, 02421
United States, Michigan
Admas Clinical Site
Detroit, Michigan, United States, 48201
Adamas Clinical Site
Farmington Hills, Michigan, United States, 48334
United States, Minnesota
Adamas Clinical Site
Golden Valley, Minnesota, United States, 55422
United States, Missouri
Adamas Clinical Site
Kansas City, Missouri, United States, 64111
Adamas Clinical Site
Saint Louis, Missouri, United States, 63110
United States, Montana
Adamas Clinical Site
Great Falls, Montana, United States, 59405
United States, Nebraska
Adamas Clinical Site
Lincoln, Nebraska, United States, 68506
Adamas Clinical Site
Omaha, Nebraska, United States, 68198
United States, Nevada
Adamas Clinical Site
Las Vegas, Nevada, United States, 89016
United States, New Mexico
Adamas Clinical Site
Albuquerque, New Mexico, United States, 87131
United States, New York
Adamas Clinical Site
Amherst, New York, United States, 14226
Adamas Clinical Site
Lake Success, New York, United States, 11042
Adamas Clinical Site
New York, New York, United States, 10029
Adamas Clinical Site
Patchogue, New York, United States, 11772
Adamas Clinical Site
Plainview, New York, United States, 11803
Adamas Clinical Site
Rochester, New York, United States, 14642
Adamas Clinical Site
Staten Island, New York, United States, 10306
United States, North Carolina
Adamas Clinical Site
Charlotte, North Carolina, United States, 28207
Adamas Clinical Site
Raleigh, North Carolina, United States, 27607
United States, Ohio
Adamas Clinical Site
Centerville, Ohio, United States, 45459
Adamas Clinical Site
Cleveland, Ohio, United States, 44195
Adamas Clinical Site
Columbus, Ohio, United States, 43214
United States, Oklahoma
Adamas Clinical Site
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Adamas Clinical Site
Portland, Oregon, United States, 97225
United States, Pennsylvania
Adamas Clinical Site
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Adamas Clinical Site
Charleston, South Carolina, United States, 29406
Adamas Clinical Site
Greer, South Carolina, United States, 29650
Adamas Clinical Site
Indian Land, South Carolina, United States, 29707
Adamas Clinical Site
Spartanburg, South Carolina, United States, 29307
United States, Tennessee
Adamas Clinical Site
Cordova, Tennessee, United States, 38018
Adamas Clinical Site
Franklin, Tennessee, United States, 37064
Adamas Clinical Site
Johnson City, Tennessee, United States, 37604
United States, Texas
Adamas Clinical Site
Houston, Texas, United States, 77030
Adamas Clinical Site
Houston, Texas, United States, 77074
Adamas Clinical Site
Round Rock, Texas, United States, 78681
United States, Utah
Adamas Clinical Site
Salt Lake City, Utah, United States, 84103
United States, Virginia
Adamas Clinical Site
Newport News, Virginia, United States, 23601
Adamas Clinical Site
Norfolk, Virginia, United States, 23502
United States, Washington
Adamas Clinical Site
Kirkland, Washington, United States, 98034
Adamas Clinical Site
Seattle, Washington, United States, 98101
Adamas Clinical Site
Seattle, Washington, United States, 98122
United States, Wisconsin
Adamas Clinical Site
Milwaukee, Wisconsin, United States, 53215
Canada, Alberta
Adamas Clinical Site
Edmonton, Alberta, Canada, T6R 2B7
Adamas Clinical Site
Lethbridge, Alberta, Canada, T1J 0N9
Canada, British Columbia
Adamas Clinical Site
Burnaby, British Columbia, Canada, V5G 2X6
Canada, Quebec
Adamas Clinical Site
Greenfield Park, Quebec, Canada, J4V 2J2
Adamas Clinical Site
Montréal, Quebec, Canada, H3A 2B4
Adamas Clinical Site
Quebec City, Quebec, Canada, G1J 1Z4
Sponsors and Collaborators
Adamas Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Director Adamas Pharmaceuticals

Layout table for additonal information
Responsible Party: Adamas Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03436199    
Other Study ID Numbers: ADS-AMT-MS301
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Amantadine
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents